Welcome to our dedicated page for Alto Neuroscienc news (Ticker: ANRO), a resource for investors and traders seeking the latest updates and insights on Alto Neuroscienc stock.
Alto Neuroscience develops clinical-stage precision medicines for neuropsychiatric disorders, using its Precision Psychiatry Platform™ to analyze EEG activity, neurocognitive assessments, wearable data and other biomarkers that may identify patient populations for its product candidates.
Company news centers on clinical data, trial initiations and pipeline decisions for programs including ALTO-207 in treatment-resistant depression and major depressive disorder, ALTO-101 in cognitive impairment associated with schizophrenia, and other candidates for bipolar depression, schizophrenia and mental health conditions. Updates also cover financial results, capital activity, regulatory designations, medical-meeting presentations and investor-conference participation.
Alto Neuroscience (NYSE: ANRO) entered a private placement (PIPE) to raise approximately $120 million in gross proceeds to fund development of ALTO-207 for treatment resistant depression.
Alto sold 2,900,000 common shares at $20.00 and pre-funded warrants for 3,100,000 shares at $19.9999 each. The company expects to start a Phase 2b in H1 2026 and a Phase 3 in early 2027, and estimates pro forma cash of approximately $275 million as of February 28, 2026.
Alto Neuroscience (NYSE:ANRO)/b) reported full year 2025 results and pipeline progress, highlighting the , a $50 million PIPE financing, and a year-end cash balance of $177 million expected to fund operations into 2028. Key clinical milestones include FDA Fast Track for ALTO-101, planned ALTO-207 Phase 2b initiation in 1H 2026, and four near-term data readouts through 2027.
Clinical signals include a PAX-D Cohen's d=0.87 for pramipexole and a meta-analytic Hedges' g=0.64 (p<0.001). Full-year R&D was $45.6M, G&A $20.7M, and net loss $63.2M.
Alto Neuroscience (NYSE: ANRO) said members of management will present in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET.
The presentation will stream live via a webcast on Alto's Investors Events and Presentations page, and a replay will be available after the event.
Alto Neuroscience (NYSE: ANRO) said management will attend two investor conferences in March 2026: TD Cowen 46th Annual Healthcare Conference (March 2-5) with a fireside chat on March 3, 2026 at 1:50 pm EST, and Jefferies Biotech on the Beach Summit (March 10-11) for one-on-one meetings.
Presentations will be available via live webcast on Alto's Investors Events and Presentations page, with replays posted after the sessions.
Alto Neuroscience (NYSE: ANRO) completed enrollment in its Phase 2 proof-of-concept crossover trial of ALTO-101 for cognitive impairment associated with schizophrenia (CIAS) on February 13, 2026. The study enrolled 83 patients across 13 U.S. sites (NCT06502964) and uses EEG biomarkers and cognitive tests to assess treatment effects.
The randomized, double-blind, placebo-controlled crossover design delivers 10 days of ALTO-101 or placebo per period with a washout, and the study is 80% powered to detect a 0.3 Cohen’s d on theta-band inter-trial coherence (primary endpoint). Topline data are expected after dosing and analysis, guiding future development.
Alto Neuroscience (NYSE: ANRO) announced a peer-reviewed invited review in the American Journal of Psychiatry (2026) establishing neuroplasticity as a core, measurable driver of psychiatric disease and treatment.
The article, co-authored by Alto leaders, argues that restoring plasticity underlies efficacy across therapies and highlights the industry gap of translatable human biomarkers—supporting Alto’s precision psychiatry platform and biomarker-driven clinical programs.
Alto Neuroscience (NYSE: ANRO) announced the issuance of U.S. Patent No. 12,521,374 on January 14, 2026, covering methods of treating depression with ALTO-207, a combination of pramipexole and ondansetron. The patent specifically claims the use of ondansetron to mitigate pramipexole-related side effects, enabling higher pramipexole dose levels to achieve antidepressant effects. The company says issued and pending claims for ALTO-207, in the U.S. and internationally, are expected to provide protection into the mid-2040s, which it says strengthens the long-term commercial opportunity for the program.
Alto Neuroscience (NYSE: ANRO) presented multiple EEG biomarker analyses at the 64th ACNP meeting (Jan 12-15, 2026) that support its precision psychiatry programs. Key results include an independent replication in 155 schizophrenia cases and 272 controls validating Theta‑ITC as a CIAS biomarker; prospective replication showing ALTO‑203 improves sustained attention, lowers theta/beta ratio, and increases wakefulness without changing sleep efficiency; and an EEG biomarker that prospectively predicted placebo response and enhanced treatment effect detection in two randomized trials.
Alto Neuroscience (NYSE: ANRO) announced that on December 2, 2025 its Compensation and Management Development Committee granted a new employee an inducement stock option for 150,000 shares under the 2025 Inducement Plan in accordance with NYSE Rule 303A.08. The option has an exercise price of $12.80 (closing price on the grant date), a 10-year term, and standard service-based vesting over four years: 25% after one year and the remainder vesting in equal monthly installments over the following 36 months. Vesting is conditioned on continued service.
Alto Neuroscience (NYSE: ANRO) reported Q3 2025 results and pipeline updates on November 12, 2025. Key clinical milestones include an FDA meeting outcome for ALTO-207 with a Phase 2b start targeted in 1H 2026 and Phase 3 by early 2027. Topline readouts expected: ALTO-101 (CIAS) 1Q 2026, ALTO-300 (MDD) mid-2026, ALTO-100 (BPD) 2H 2026. Blinded PK analyses were positive for ALTO-101 (100% PK positive) and ALTO-100 (96% PK positive). The company closed a $50M PIPE and had $184.2M cash as of October 31, 2025, expected to fund operations into 2028.